One month to go until our Protein Degradation in Focus Symposium begins!

We can't wait to welcome you to Dundee.

Please use the symposium hashtag #TPDFocus to share your experiences with us during the event!

buff.ly/47S4y1Q

#TargetedProteinDegradation

Discovery of a Meisoindigo-Derived PROTAC as the ATM Degrader: Revolutionizing Colorectal Cancer Therapy via Synthetic Lethality with ATR Inhibitors | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/ac…

Ternary Complex‐Templated Dynamic Combinatorial Chemistry for the Selection and Identification of Homo‐PROTACs Angewandte Chemie Alessio Ciulli onlinelibrary.wiley.com/doi/10.1002/an…

Breaking Bad Proteins—Discovery Approaches and the Road to Clinic for Degraders Cells MDPI mdpi.com/2728104

Discovery and Characterization of a Novel Cereblon-Recruiting PRC1 Bridged PROTAC Degrader | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/ac…

Discovery of First-in-Class PROTAC Degraders of SARS-CoV-2 Main Protease | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/ac…

Discovery of the First-in-Class G9a/GLP PROTAC Degrader | Journal of Medicinal Chemistry pubs.acs.org/doi/10.1021/ac…

Use of ionic liquids in amidation reactions for proteolysis targeting chimera synthesis - now published in Organic & Biomolecular Chemistry pubs.rsc.org/en/content/art…

Novartis is adding another weapon to its arsenal of oncology therapies, paying Arvinas $150 million upfront for rights to a phase 3-ready protein degrader that could treat a wide range of prostate cancer patients.
fiercebiotech.com/biotech/novart…

#NEWS : Arvinas ($ARVN) enters into a transaction with Novartis, including a license agreement for Arvinas’ second generation PROTAC® androgen receptor (AR) degrader.

Read the full press release here: rb.gy/pvjft6

USP7-Based Deubiquitinase-Targeting Chimeras Stabilize AMPK | Journal of the American Chemical Society pubs.acs.org/doi/10.1021/ja…

Liposomal STAT3-Degrading PROTAC Prodrugs Promote Anti-Hepatocellular Carcinoma Immunity via Chemically Reprogramming Cancer Stem Cells | Nano Letters pubs.acs.org/doi/10.1021/ac…

The three-part New Drugs on the Horizon Series at the AACR Annual Meeting 2024 wrapped up this morning. A total of 12 first-time disclosures were presented.
bit.ly/3J8AmVM
#AACR24

SuFEx-based chemical diversification for the systematic discovery of CRBN molecular glues sciencedirect.com/science/articl…

Sulfatase-Induced In Situ Formulation of Antineoplastic Supra-PROTACs | Journal of the American Chemical Society pubs.acs.org/doi/10.1021/ja…

Development of a First-in-Class RIPK1 Degrader to Enhance Antitumor Immunity biorxiv.org/content/10.110…

Discovery of novel co-degradation CK1α and CDK7/9 PROTACs with p53 activation for treating acute myeloid leukemia sciencedirect.com/science/articl…

AR-PROTAC BMS-986365 is a potent & rapid AR degrader with enzalutamide-like antagonist potency, low AR agonism, weak activity against AR L702H, claimed to be selective against CRBN neosubstrates (data not shown) & allows to overcome AR feedback up-regulation. #AACR24 #TPD

Congratulations to the 2024 AACR Fellows #AACR24 , strong showing of chemical biology including PROTAC inventor Craig Crews and Sarafan ChEM-H institute scholar Nathanael Gray!